AusperBio secures $120 million Series C to push AHB‑137 toward Phase 3 and expand its HBV pipeline
Executive summary: AusperBio completed a $120 million Series C funding round to advance AHB‑137 toward Phase 3 testing and commercial readiness, while also accelerating AHB‑171 and combination therapies. The capital reduces financing risk for a pivotal Phase 3 trial, supports commercialization preparations, and broadens the company’s HBV pipeline, potentially accelerating functional‑cure options for patients.
Who is involved: AusperBio (the biotech company), its investors (unspecified), and the clinical teams developing AHB‑137, AHB‑171 and combination regimens.
Likely next (inference): Initiation of the Phase 3 registrational program for AHB‑137, advancement of AHB‑171 toward clinical trials, and exploration of partnership or licensing opportunities for its combination approaches.
AusperBio has closed a $120 million Series C round to advance its lead hepatitis B virus (HBV) candidate AHB-137 into a Phase 3 registrational program and prepare for potential commercialization, while also accelerating the clinical development of AHB-171 and next-generation combination regimens targeting a functional cure. The financing comes shortly after the company dosed the first patient in a clinical study of AHB-171, an investigational therapeutic vaccine, signaling parallel progress across its pipeline. The capital infusion extends AusperBio's runway to execute late-stage trials and build commercial infrastructure in a disease area where durable viral suppression remains an unmet need. The investment reflects continued investor appetite for HBV assets despite a crowded competitive field. Aligos Therapeutics recently completed enrollment in its Phase 2 B-SUPREME study of pevifoscorvir sodium, another candidate pursuing functional cure, underscoring the intensity of clinical activity. AusperBio's strategy of advancing both a capsid assembly modulator (AHB-137) and an immunotherapeutic (AHB-171) positions it to explore combination approaches that could differentiate its profile if efficacy and safety data support synergistic effects. Near-term milestones include the initiation of AHB-137's Phase 3 program, ongoing dose escalation for AHB-171, and potential combination data readouts that could inform partnership discussions or regulatory strategy. The company's ability to translate this funding into clinical advancement will be closely watched as the HBV landscape evolves toward multi-mechanism regimens.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Phase 3 Momentum (Base Case) (50%)
Increased valuation and potential M&A interest as AHB-137 transitions to registrational trials.
- Successful initiation of Phase 3 trial protocols
- Positive interim safety data from AHB-171 studies
Combination Synergy Breakthrough (Upside) (25%)
Dominance in the HBV functional cure market through a differentiated dual-mechanism therapy.
- Positive preclinical or early-phase data showing synergy between AHB-137 and AHB-171
- Securing a strategic partnership with a major pharmaceutical player
Clinical or Competitive Setback (Downside) (25%)
Burn rate accelerates without clinical validation, leading to a liquidity crunch or down-round.
- Delay in Phase 3 enrollment for AHB-137
- Negative safety signals in AHB-171 dose escalation studies
What to watch
- Phase 3 trial initiation announcement (90 days)
- AHB-171 dose escalation data updates (60 days)
- Competitive clinical readouts from Aligos Therapeutics (90 days)
Timeline
- — AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies (PR Newswire)
- — AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171 (PR Newswire)
- — Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection (GlobeNewswire)
Analysis — what this means
Sectors affected
- HBV therapeutics
- Oligonucleotide‑based antiviral drugs
Regulatory implications
- FDA will review Phase 3 data for AHB‑137 under the standard IND/NDA pathway
- EMA will assess any EU marketing authorization application for AHB‑137
- Clinical trial oversight will follow ICH‑GCP guidelines for HBV studies
Historical parallels
- Gilead’s launch of tenofovir alafenamide for HBV in 2016
- Approval of entecavir (Baraclude) for chronic HBV in 2005
- Roche’s PEG‑interferon alfa‑2a approval for HBV in 2002
Key entities
Sources
- AusperBio Completes $120 Million Series C Financing to Advance AHB-137 Toward Potential Commercialization and Expand Next-Generation HBV Therapies — PR Newswire
- AusperBio Announces First Patient Dosed in Clinical Study of Investigational HBV Candidate AHB-171 — PR Newswire
- Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection — GlobeNewswire